Global ADHD Therapeutics Market maximizemarketresearch.com

By drug type, the stimulants segment was valued $xx Mn in 2020, and is expected to dominate the ADHD market in the forecast period. The stimulants are considered first-line treatments for ADHD, supported by decades of research and a history of robust response, good tolerability, and safety across the lifespan. Stimulants are classified by the US Food and Drug Administration (FDA) and the Drug Enforcement Agency as schedule 2 agents.